[Possibilities of using recombinant human deoxyribonuclease I in otorhinolaryngology].

Autor:	Eremeeva KV; Sechenov First Moscow State Medical University, Moscow, Russia., Svistushkin VM; Sechenov First Moscow State Medical University, Moscow, Russia., Sinkov EV; Sechenov First Moscow State Medical University, Moscow, Russia., Mironova AR; Sechenov First Moscow State Medical University, Moscow, Russia., Sobolev VP; Sechenov First Moscow State Medical University, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Vestnik otorinolaringologii [Vestn Otorinolaringol] 2023; Vol. 88 (2), pp. 59-66.
DOI:	10.17116/otorino20228802159
Abstrakt:	Annotation: Dornase alfa (Pulmozyme, Tigerase) is a purified solution of recombinant human DNase, clinically developed for the treatment of pulmonary diseases in patients with cystic fibrosis (CF). The action of the drug is aimed at destroying the viscous secretion, rich in DNA strands of neutrophils, through their fragmentation, the density of the secretion decreases, and the aeration of the lower respiratory tract improves. The similarity of pathological processes with the formation of viscous exudate on the surface of the mucous membrane in diseases of the upper respiratory tract and ear initiated studies on the use of Dornase alpha in otorhinolaryngology. Material and Methods: The analysis of materials of domestic and foreign authors on the effectiveness of the use of the drug Dornase alfa in otorhinolaryngology was carried out. Results: The review included 132 patients (10 studies) in whom Dornase alfa was used to treat CF-associated nasal and paranasal sinus diseases. Analysis of the literature revealed only 3 studies, one of which consisted of two parts, examining the effect of Dornase alpha on middle ear exudate: two studies were demonstrated in an animal model; one - in vitro on samples of middle ear effusion which were aspirated through a myringotomy incision from patients with recurrent acute otitis media; and one in clinical 40 patients (40 ears) for hydrolysis of exudate in the tympanostomy tubes. Conclusion: Analysis of studies on the use of Dornase alfa demonstrates an improvement in clinical symptoms in all patients with CF and chronic rhinosinusitis. In experimental studies on an animal model, as well as in vitro research on exudate from the middle ear, Dornase alfa has demonstrated high efficacy and safety. Dornase alfa is a drug with high potential, further research is needed for wider use in ENT practice, especially in otiatrics.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu